Xianbin Zhang, MD, PhD, Shenzhen University, China
Milad Ashrafizadeh, PhD, Sabanci University, Turkey
Jiansong Ji, MD, PhD, Fifth Affiliated Hospital of Wenzhou Medical University, China
This collection is no longer accepting submissions.
Image Credit: top images / Generated with AI / Stock.adobe.com
Lung cancer remains the leading cause of cancer-related mortality worldwide, necessitating the development of new treatment strategies. Arachidonic acid (ARA), a polyunsaturated fatty acid, shows promise in ca...
Pancreatic cancer (PC) ranks sixth globally among cancer deaths, imposing a significant burden on healthcare systems worldwide. Although diet is known to be a major risk factor, Although diet is a well-establi...
The Correction to this article has been published in Lipids in Health and Disease 2025 24:90
Lipid metabolism is a well-regulated process essential for maintaining cellular functions and energy homeostasis. Dysregulation of lipid metabolism is associated with various conditions, including cardiovascul...
Liver cancer is a highly lethal malignant tumor with a high incidence worldwide. Therefore, its treatment has long been a focus of medical research. Although traditional treatment methods such as surgery, radi...
The Correction to this article has been published in Lipids in Health and Disease 2025 24:60
Bladder cancer is one of the most common malignancies of the urinary system. Despite significant advances in diagnosis and treatment, the compromised therapeutic effect of chemotherapeutic agents, such as Oxal...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an asymptomatic, multifaceted condition often associated with various risk factors, including fatigue, obesity, insulin resistance, metabolic...
Research has indicated that treatment with rosuvastatin can improve liver pathology in metabolic-associated fatty liver disease (MAFLD) patients and that treatment with Bifidobacterium can improve MAFLD. Therefor...
Pancreatic neoplasm, a highly aggressive and often fatal cancer, poses challenges due to late detection and nonspecific symptoms. Therefore, both early diagnosis and appropriate therapeutic approaches are nece...
Triple-negative breast cancer (TNBC) continues to pose a significant obstacle in the field of oncology. Dysregulation of lipid metabolism, notably upregulated ketogenesis, has emerged as a hallmark of TNBC, ye...
Bufalin (BA) is a potent traditional Chinese medicine derived from toad venom. It has shown significant antitumor activity, but its use is limited by cardiotoxicity, which necessitates innovative delivery meth...
The management of male infertility continues to encounter an array of challenges and constraints, necessitating an in-depth exploration of novel therapeutic targets to enhance its efficacy. As an eight-carbon ...
The accumulation of reactive oxygen species (ROS) within the bone marrow microenvironment leads to diminished osteogenic differentiation and heightened lipogenic differentiation of mesenchymal stem cells resid...
Abnormal metabolism and synthesis of lipids is involved in a variety of diseases, including cancer, diabetes, neurodegenerative diseases, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and cardiovascular diseases. Several small molecule inhibitors are used to fight lipid metabolic dysfunction. However, it is unavoidable that the inhibitors are short-lived or nonspecifically distributed in the body after injection or oral administration, and ultimately, only a small portion of the administered drugs bind to the target. Therefore, designing drug delivery systems to target the regulation of lipid metabolism is considered to be a promising strategy for the effective treatment of the above diseases. Moreover, the clinical significance of lipid-based mechanisms has been evaluated, and alterations in lipid levels in serum can affect the prognosis of patients. The physiological microenvironment remodeling and function of the immune system are also modulated by lipid metabolism in diseases. The aim of this Collection is to encourage submissions incorporating interdisciplinary approaches that construct advanced nanoplatforms to effectively deliver chemotherapeutic drugs, proteins, biomacromolecules, siRNA, mRNA and other regulators. In addition, the latest advances, emerging trends and strategies in the areas of lipid-related mechanisms and the mutual interactions between lipids and nanoparticles are also welcome. This Collection provides a platform for communication and discussion of the pharmacological mechanism of nanobiotechnology and lipid metabolism.
Keywords: Nanodrug delivery system, lipid metabolism, fatty acid, small molecule inhibitor, gene, metabolic diseases
The topics of interest include but are not limited to:
• Nanoplatforms of lipid metabolism related regulators and their evaluation in vitro and in vivo
• Delivery of molecules, natural products, or nucleic acids to treat cancer, diabetes, neurodegenerative diseases, NAFLD, NASH, cardiovascular diseases, etc., via reversal of abnormal lipid metabolic dysfunction
• Molecular pathways of nanodrug delivery systems regulating lipid synthesis and metabolism in metabolic diseases
• Mutual interactions between intracellular lipids and nanoparticles
• Effect of nanoparticles and materials on lipid metabolism
Questions to be answered:
• Whether the nanomaterials themselves affect intracellular lipid synthesis and metabolism?
• Which specific molecular pathways are involved in the drug delivery systems that regulate lipid synthesis and metabolism in diseases?
• Are there any novel strategies to target lipid metabolism by using natural products?
• How exactly can drug delivery systems affect the response of cells to therapy by regulating lipid metabolism?
• Challenges and limitations associated with nanomaterial-based drug delivery systems targeting lipid metabolism
Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Nanomaterials/Biomaterials Target Lipid Metabolism and Fight Diseases" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.